lanreotide
Selected indexed studies
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (N Engl J Med, 2014) [PMID:25014687]
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. (Endocrine, 2021) [PMID:33052555]
- The safety of lanreotide for neuroendocrine tumor. (Expert Opin Drug Saf, 2019) [PMID:30582380]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (2014) pubmed
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. (2021) pubmed
- The safety of lanreotide for neuroendocrine tumor. (2019) pubmed
- Lanreotide for the treatment of acromegaly. (2009) pubmed
- Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. (2016) pubmed
- Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. (2016) pubmed
- An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors. (2024) pubmed
- Pharmacokinetic evaluation of lanreotide. (2010) pubmed
- Lanreotide Autogel: a review of its use in the management of acromegaly. (2008) pubmed
- Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases. (2015) pubmed